Patients in foreign countries who could not stop using medical-grade heroin with conventional traditional treatment methods were successfully treated when they were provided heroin in a supervised setting, a report recently released by the RAND Corporation found.
These findings led RAND researchers to suggest the same treatment, also known as heroin-assisted treatment, be piloted and studied in the U.S. as a possible way to help turn the tide of the opioid epidemic.
“Current levels of opioid-related morbidity and mortality in the United States are staggering. Data for 2017 indicate that there were more than 47,000 opioid-involved overdose deaths, and one in eight adults now reports having had a family member or close friend die from opioids,” Beau Kilmer, PhD, MPP, co-director of Rand’s Drug Policy Research Center, told Healio.com/Family Medicine.
“Increasing the availability and reducing the costs of approved medications for those with an opioid use disorder is imperative; however, jurisdictions addressing opioid use disorder and overdose may wish to consider additional interventions. Two interventions that are implemented in some other countries but not in the United States are heroin-assisted treatment and supervised consumption sites,” he continued.
Although heroin cannot be prescribed in the U.S. because it is a Schedule I drug, randomized controlled trials with the drug are allowed, according to a RAND Corporation press release.
Kilmer and colleagues interviewed more than 150 people on multiple sides of the treatment spectrum stateside to assess the value of these additional interventions. They also discussed the interventions with more than two dozen stakeholders abroad and analyzed several randomized clinical trials involving these interventions in the U.K., Canada, the Netherlands and Switzerland. Some of their findings included:
- Heroin-assisted treatment is an “established treatment option” for those who had not benefited from methadone or buprenorphine maintenance treatment in the Netherlands.
- Supervised injectable heroin and supervised injectable hydromorphone showed similar effectiveness with regard to treatment retention, illicit heroin use, illegal activities, physical health and mental health in the first 6-month phase of a randomized clinical trial involving 202 patients Canada. In addition, the hydromorphone group had significantly fewer serious adverse events related to the study medication vs. the heroin-assisted treatment group. Researchers noted that hydromorphone is a Schedule II drug, and may face fewer barriers in the U.S.
- Randomized controlled trials involving heroin-assisted treatment in all countries consulted — except for the Netherlands — resulted in higher relative treatment retention rates, although differences were not significant for the “relatively small” number of participants in the Belgian (n = 74), Spanish (n = 62) and Swiss (N = 51), trials. Across all trials, treatment retention rates among the heroin-assisted treatment groups are relatively high, ranging from 67% to more than 90%.
“Given 1) the increased mortality associated with fentanyl; (2) the fact that some people who use heroin may not respond well to existing medications for [opioid use disorder]; (3) [heroin-assisted treatment’s] successful implementation abroad; and (4) questions concerning whether the success would carry over to the United States, heroin-assisted treatment trials should be conducted in some of the United States jurisdictions with good social services and existing provision of medication treatment for opioid use disorder,” Kilmer said in the interview.
RAND researchers are suggesting heroin-assisted treatment be piloted and studied in the U.S. as a possible way to help turn the tide of the opioid epidemic.
Researchers also noted several insights for piloting and studying heroin-assisted treatment in the U.S., including:
- It is more expensive than oral methadone but because of the treatment’s effect on reducing criminal activity among its target population, it may be more cost-beneficial for clients who are resistant to try standard treatments.
- It faces “significant” legal issues surrounding the implementation of supervised consumption sites.
- It would likely “face substantial resistance” from community members, particularly in rural areas that do not have syringe exchange programs or basic treatment services.
- It is important to be aware of possible scale limitations and costs with heroin-assisted treatment and supervised consumption sites.
- It might be beneficial to view heroin-assisted treatment and supervised consumption sites as exemplars of a broader strategy, not as the only option within their class.
Kilmer pointed out the most important thing he felt primary care physicians should be doing as a result of the RAND report.
“[PCPs] can facilitate discussions with other physicians and community members about how to best address opioid use disorders and overdoses in their communities. There are many options worthy of dispassionate discussion, some of which are implemented in other countries but not in the United States.” – by Janel Miller
Reference: Rand Corporation. “Considering heroin-assisted treatment and supervised drug consumption sites in the United States.” Rand.org.
Disclosures: The authors report no relevant financial disclosures.